1. Abdulaziz A. Al-Jafari and Anthony Cryer. Enzyme inhibitory activity of chicken anti-lipoprotein  lipase serum. Biochem. Soc. Trans. 13,216-217 (1985).
2. Abdulaziz A. Al-Jafari, S. R. Lee, R. K. Tume and A. Cryer. Isolated adipocytes: an assessment  of cell surface changes during their preparation. Cell. Biochem. Funct.4, 169-179 (1986).
3. Abdulaziz A. Al-Jafari and Anthony Cryer. The lipoprotein lipase of white adipose tissue Studies on the intracellular distribution of the adipocyte-associated enzyme. Biochem. J. 236, 749-756 (1986).
4. Abdulaziz A. Al-Jafari and Anthony Cryer. The lipoprotein lipase of white adipose tissue. Changes in the adipocyte cell-surface content of enzyme in response to extracellular effectors in vitro. Biochem. J. 238, 239-246 (1986)
5. Abu-Salah, K.M., Al-Duhaiman, A.S., Gorban, A.M. and Al-Jafari, A.A. Towards an application oriented biochemistry curriculum. Biochem. Edu. 18, 28-31 (1991).
6.  Abdulaziz A. Al-Jafari. The effect of tetrabutylammonium ion on chicken brain acetylcholinesterase activity in vitro. Drug. Chem. Toxicol. 15, 295-312 (1992).
7. Abdulaziz A. Al-Jafari. The toxicological effect of cyclophosphamide on acetylcholinestera activity. Toxicol Lett. 66, 125-131 (1993).
8. Abdulaziz A. Al-Jafari. The inhibitory effect of tetramethylene diamine on water soluble and membrane bound acetylcholinesterase activity. Int. J. Biochem. 25, 319-324 (1993).
9. Abdulaziz A. Al-Jafari. Investigation of the reversible inhibition of camel (Camelus dromedaries) acetylcholinesterase by tetracaine. Comp. Biochem. Physiol. 105 C, 323-327 (1993).
10. Abdulaziz A. Al-Jafari and Mohammed A. Kamal. The preparation and kinetic properties of  multiple forms of chicken brain acetylcholinesterase. Cell. Biochem. Funct. 12, 209-216 (1994).
11. Abdulaziz A. Al-Jafari and Ali S. Duhaiman. Kinetics of the inhibition of acetylcholinesterase from pigeon brain by procaine hydrochloride. Cell. Biochem. Funct. 12, 29-35 (1994).
12. Al-Saleh, S.S., Rabbani, N., Al-Jafari, A.A. and Duhaiman, A.S. A rapid fractionation method for the desert cobra venom (Walterinnesia aegyptia). Med. Sci. Res. 22, 659-660 (1994)
13. Abdulaziz A. Al-Jafari, Ali S. Duhaiman and Mohammed A. Kamal. Inhibition of human acetylcholinesterase by cyclphosphamide. Toxicology 96, 1-6 (1995).
14. Abdulaziz A. Al-Jafari, Mohammed A. Kamal and Ali S. Duhaiman. The mode of inhibition of human erythrocyte membrane-bound acetylcholinesterase by cisplatin in vitro. J. Enz. Inhibit. 8, 281-289 (1995).
15. Alhomida, A.S., Al-Jafari, A.A., Junaid, A and Duhiman, A.S. Sex, Age and diabetes-related changes in total, free and acylcarnitine in human plasma. Med. Sci. Res. 23, 167-169 (1995).
16. Abdulaziz A. Al-Jafari. Kinetics for the inhibition of acetylcholinesterase from human erythrocyte by cisplatin. Int. J. Biochem. Cell. Boil. 27, 965-970 (1995).
17. Ali S. Duhiman, Nayar Rabbani, Abdulaziz A. Al-Jafari and Abdullah S. Alhomida. Purification and some properties of two phopholipases and a toxin from the venom of desert cobra (Walterinnesia aegyptia). Biochem.Mol.Biol.Int. 37, 1011-1020 (1995).
18. Abdulaziz A. Al-Jafari. Mercuric chloride effects on the kinetic parameters of human erythrocyte membrane bound acetylcholinesterase. Biochem. Mol. Biol. Int. 36, 1243-1253 (19950
19. Ali S. Duhiman, Nayar Rabbani, Abdulaziz A. Al-Jafari and Abdullah S. Alhomida. Purification and characterization of zeta-crystallin from the camel lens. Biocem.Biophys.Res Commun. 215, 623-640 (1995).
20. Abdulaziz A. Al-Jafari, M. A. Kamal, Ali S. Duhiman, and Abdullah S. Alhomida. Acetylcholinesterase from desert cobra (Walterinnesia aegyptia) venom: Optimization and kinetics study. Mol. Cell. Biochem. 151, 21-26 (1995).
21. A. S. Alhomida, A S. Duhiman., A. A. Al-Jafari and M.A. Junaid. Determination of L-carnitine, acylcarnitine and total carnitine levels in plasma and tissues of Camel (Camelus dromedaries). Comp. Biochem. Physiol. 111B, 441-445. (1995).
22. Abdulaziz A. Al-Jafari and Mohammed A. Kamal. Optimization and kinetics of human erythrocyte membrane-bound acetylcholinesterase. Biochem. Mol. Biol. Int.38, 577-586 (1996)
23. Mohammed A. Kamal and Abdulaziz A. Al-Jafari. The preparation and kinetic analysis of multiple forms of human erythrocyte acetylcholinesterase. Prep. Biochem. Biotech. 26,105-119 (1996).
24. Mohammed A. Kamal and Abdulaziz A. Al-Jafari. Estimation and correlation of IC50 with time for the inhibition of human erythrocyte acetylcholinesterase by cisplatin. Cell Pharmacol. 3, 45-48 (1996).
25. A S. Duhiman, A. S. Alhomida, N. Rabbani, M.A. Kamal and A.A. Al-Jafari. Purification and characterization of acetylcholinesterase from desert cobra (Walterinnesia aegyptia).Biochimie. 77, 46-50 (1996).
26. Mohammed A. Kamal, Faizul H. Nasim and Abdulaziz A. Al-Jafari. Investigation of the effect of anti-neoplasstic drugs: cyclophosphamide, cisplatin and methotrexate on the turnover kinetics of human erythrocyte acetylcholinesterase. Biochem. Mol. Biol. Int. 39,293-302 (1996).
27. Mohammed A. Kamal, Faizul H. Nasim and Abdulaziz A. Al-Jafari. In vitro inhibition of human erythrocyte acetylcholinesterase (EC 3.1.1.7) by an anti-neoplasstic drug methotrexate. Mol. Cell. Biochem 159, 47-53 (1996).
28. A. S. Alhomida, A.A. Al-Jafari, A S. Duhiman, N. Rabbani, and M.A. Junaid. Kinetic Properties of purified carnitine acetyltransferase from the skeletal muscle of Arabian camel (Camelus dromedrius). Biochimie. 78, 204-208 (1996).
29. Abdulaziz A. Al-Jafari and Mohammed A. Kamal. Investigation of the effect of    tetrahydroaminoacridine on turnover kinetics of camel (Camelus dromedrius) retina acetylcholinesterase. Biochem. Mol. Biol. Int. 39, 917-922 (1996).
30. Abdulaziz A. Al-Jafari, Fareeda A. Al-Khwyter, Mohammed A. Kamal. and Abdullah S. Alhomida. Kinetics for camel (Camelus dromedrius) retina acetylcholinesterase inhibition by methotrexate in vitro. Jpn. J. Pharmacol. 72, 49-55 (1996)
31. Fareeda A. Al-Khwyter, Mohammed A. Kamal and Abdulaziz A. Al-Jafari. The inhibitory effect of cyclophosphamide on camel retina acetylcholinesterase activity. Toxicol. Lett. 87, 69-76 (1996).
32. A. S. Alhomida, A S. Duhiman, A. A. Al-Jafari, S. Sobki and A. Al-Khader. Serum, total,  free and acylcarnitine concentrations in chronic glomerunlneophritis patients. Med. Sci. Res. 24, 495-498 (1996).
33. Abdulaziz A. Al-Jafari. Mohammed A. Kamal, Ali. S. Duhiman, and A. S. Alhomida. Kinetics of the inhibition of acetylcholinesterase from desert cobra (Walterinnesia aegyptia) Venom by local anesthetics: procaine and tetracaine. J.Enz.Inhihit.11, 123-134 (1996).
34. Abdulaziz A. Al-Jafari, M A. Junaid and A. S. Alhomida. Investigation of the influence of theophylline feeding on total, free short-chain acyl and long-chain acyl carnitine levels in skeletal muscle and liver of rats. In vivo. 10, 569-574 (1996)
35. A. S. Alhomida, A S. Duhiman, A. A. Al-Jafari and M.A. Junaid. Purification of carnitine acetyltransferase from skeletal muscle of the camel (Camelus dromedrius). Moll. Cell. Biochem. 165, 95-101 (1996)
36. Abdulaziz A. Al-Jafari. The nature of the inhibition of camel retina acetylcholinesterase (E.C.3.1.1.7) activity by tetrahydroaminoacridine. J.Ocul. Pharmacol.Ther.12, 503-514 (1996)
37. Abdulaziz A. Al-Jafari. The inhibitory effect of neuromuscular blocking agent gallaminetriethiodide on camel retina acetylcholinesterase activity. Toxicol. Lett. 90, 45-51 (1997).
38. Abdulaziz A. Al-Jafari, Mohammed A. Kamal and Abdullah S. Alhomida. Thermodynamic
investigation of camel retina acetylcholinesterase inhibition by cyclophosphamide. J. Enz. Inhibit. 11, 275-283 (1997).
39. A. S. Alhomida, M.A. Junaid and A. A. Al-Jafari. The distribution of total, free, short-chain   acyl and long-chain acyl carnitine in ocular tissues of the camel (Camelus dromedrius). (Camelus dromedrius). J.Ocul. Pharmacol.Ther.13, 381-387 (1997).
40. J.M. al-Ghamdi, A. A. Al-Jafari. and A. S. Alhomida. Impact of chronic haemodialysis treatment on whole-blood and serum total dehydro-ascorbate and ascorbate concentrations in Saudi patients with chronic glomerulonephritis. Med. Sci. Res. 25, 47-50 (1997) 
41. Abdullah S. Alhomida, Mohammed A. Kamal and Abdulaziz A. Al-Jafari. Evaluationof the nature of camel retinal acetylcholinesterase inhibition by hexamethonium. J. Enz. Inhibit. 12, 303-313 (1997).
42. Mohammed A. Kamal, Mohammed S. Bakker and Abdulaziz A. Al-Jafari. Estimation and correlation of IC50 for the inhibition of human erythrocyte acetylcholinesterase byCis-Diamminediaquaplatinum. Anticancer. Res. 17,  4483-4486 (1997).
43. Abdulaziz A. Al-Jafari, Mohammed A. Kamal, and Abdullah S. Alhomida. On the the inhibition of camel retina acetylcholinesterase activity by cycloheximide in vitro. Cell. Boil. Toxicol. 14, 167-174 (1998)
44.  Abdulaziz A. Al-Jafari, Fareeda A. Al-Khwyter and Mohammed A. Kamal. Kinetics of the inhibition of acetylcholinesterase in camel retina by cisplatin. Cancer Lett. 128, 79-86 (1998)
45. Abdulaziz A. Al-Jafari, Mohammed A. Kamal and Abdullah S. Alhomida. Sensitivityof bovine retinal acetylcholinesterase (E.C 3.1.1.7) toward tacrine: kinetic characterization. J. Biochem. Mol. Toxicol. 12, 245-251 (1998).
46. J.M. Al-Ghamdi, A. A. Al-Jafari. and A. S. Alhomida, S.H. Sobki, and A.A. Al-khaddar. WholeBlood total, reduced and oxidized ascorbic acid level in Saudi patients with chronic renal failure influence of gender and chronic haemodialysis treatment. Med. Sci. Res. 26, 343-347 (1998).
47. Abdulaziz A. Al-Jafari, Mohammed A. Kamal, Nigel H. Grieg, Abdullah S. Alhomidaand Elaine R. Perry. Kinetics of human erythrocyte acetylcholinesterase inhibition by a novel derivatives of physostigmine: Phenserine. Biochem. Biophys. Res. Commun. 248, 180-185 (1998).
48. J.M. Al-Ghamdi, Abdulaziz A. Al-Jafari and Abdullah S. Alhomida. Investigation of theeffects of gender and chronic hemodialysis treatments on serum vitamin C (ascorbate) and itsoxidized metabolites concentrations in chronic renal failure patients. Biomed. Res. 9, 115-123 (1998).
49. Mohammed A. Kamal and Abdulaziz A. Al-Jafari Kinetic constants for the inhibition ofcamel retinal acetylcholinesterase by the carbamate insecticide lannate. J.Biochem. Mol. Toxicol. 13, 41-46 (1999).
50.  Mohammed A. Kamal, Faizul H. Nasim and Abdulaziz A. Al-Jafari. Human erythrocyteacetylcholinesterase inhibition by cis-diamminediaquaplatinum (II): a novel kineticapproach. Cancer. Lett. 138, 115-119 (1999).
51. Mohammed A. Kamal and Abdulaziz A. Al-Jafari. Dual substrate model for novel Approach towards a kinetic study of acetylcholinesterase inhibition by diazinon. J. Enz. Inhibit. 2000.
52. Mohammed A. Kamal, Nigel H. Greig, Abdullah S. Alhomida and Abdulaziz A. Al-Jafari. Kinetics of  human acetylcholinesterase inhibition by novel experimental Alzheimer therapeutic agent, Tolserine. Biochem. Pharmacol. 60, 561-570, 2000.
53. Mohammed A. Kamal, Faizul H. Nasim and Abdulaziz A. Al-Jafari. Graphical kinetic approach forestimation of various new constants for inhibition of acetylcholinesterase by cisplatin. Paks. J. Biol. Sci. 3(6) 920-923, 2000.
54. Abdulaziz A. Al-Jafari, Mohammed A. Kamal, Abdullah S. Alhomida and Nigel H. Greig. Kinetics of rat brain acetylcholinesterase inhibition by two experimental Alzheimer's disease drugs, phenserine and tolserine. J. Biochem. Mol. Biol.Biophys. 4, 323-335, 2000.
55.  N. J.  Siddiqi,  A. A. Al-Jafari  and A. S. Alhomida. Investigation of total, free, peptide-bound, protein-bound, soluble and insoluble collagen hydroxyproline content in tissues from the Arabian camel (Camelus dromedaius). Cell. Biochem. Funct. 18, 243-248 (2000)
56.    A. S.  Alhomida, Ali S. Al-Rajhi and  Abdulaziz A. Al-Jafari. Thermodynamic analysis ofacetylcholinesterase inhibition by an anti-Alzheimer's drug, tacrine by the development ofdual substrate and temperature model. Proc. Nation. Sci. Counc. 4, 108-115  (2000).
57.   . J.M. Al-Ghamdi, A. A. Al-Jafari, A. S.  Alhomida, S.H. Sobki, M.H. Al-Sulaiman. Chronichemodialysis treatment on whole-blood and serum levels of total, oxidized ascorbic acid in adult chronic pyelonephritis patients. Med. Biochem. 1, 167-174 (2000)
58.   H.A. Al-Madani, A. A. Al-Jafari. A. S. Alhomida, N. J.  Siddiqi, A. A. Al-Khader. A comparativestudy of  carnitine removal rate during two different haemodilyser membranes. Med. Sci. Res., 23-27, (2000).
59. A. A. Amro,  A. A. Al-Jafari, M. R. Al-Fagih M. Tajedin, and H.B. Qavi. Frequency of occurrence of  cytomegalovirus and Chlamydia pneumonia in lymphocytes of atherosclerotic patients. Cent. EurPubl. Health, 2, 106-108. (2001)
60. Muhammad A. kamal and Abdulaziz a. Al-Jafari. A Graphical kinetic analysis model for the inhibition of acetylcholinesterase by anti-alzheimer’s drug, tacrine. Saudi J.Biol.Sci, 8 (2), 113-116 
61.  Mohammed A. Kamal, Nigel H. Greig, and  Abdulaziz A. Al-Jafari. A new, simple and economical approach to analyze the inhibition kinetics of acetylcholinesterase using tolserine. Emir. Med. J. 20 (3),  333-337, 2002.
62. Mohammed A. Kamal, Abdulaziz A. Al-Jafari, Qian-Sheng Yu and Nigel H. Greig. Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine. Biochem. Biophys. Acta1760, 200-206 (2006).
63. Ebtesam  M Al-Olayan, Abdulaziz A. Al-Jafari. Mosquito’s acetylcholinesterase and insecticides: interactions between the AChE and OP and carbamates. J. Entomol. Res. 33 (1), 2009.
64. Mohammed A. Kamal,  M. Reale and Abdulaziz A. Al-Jafari. Multiple approaches to analyse the data for rat brain acetylcholinesterase inhibition by cyclophosphamide. Neurochem Res. 35, 1501- 1509, 2010
65. Abdulaziz  A. Al-Jafari, Marcel Re ale and  Mohammed A. Kamal. Human platelet acetylcholinesterase inhibition by cyclophosphamide. CNS & Neurological Disorders.  Drug Targets- 2011 
66. Abdulaziz A. Al-Jafari, Mohamed S. Daoud, Abdulelah F. Mobeirek  and Mohammad S. Al Anazi .  polymorphisms at the lipoprotein gene and their association with coronary artery disease in Saud
population Int. J. Mol. Sci. 13, 7559-7574, 2012
67. - Daoud MS, Ataya F, Fouad D, Al-Hazzani AA, Shehata AI and Al-Jafari AA. Associations of three lipoprotein lipase gene polymorphisms, lipid profiles and coronary artery disease. Biomedical Reports 2013; 1(4): 573-582.
68. - Al-Hazzani AA, Shehata AI, Moubayed NMS, Al-Jafari AA, Ataya F, Daoud MS, Rizwana H, Al-Houri HJ and El-Gaaly GA. Pomegranate (Punicagranatum) from ancient roots to modern life known with a potent antibacterial activity. Annals of Biological Research 2013; 4(5): 75-87
69. Zarger S. and Abdulaziz A. Al-Jafari. Involvement of ATP - binding cassette, subfamily A (ABCA1) polymorphism with susceptibility to Coronary arter disease (CAD) in Saudi population. Biomed Rep. 2013 Nov; 1(6): 883–888.
 
70. Farid S. Ataya, Abdulaziz A. Al-Jafari, Mohamad S. Daoud Genomics, proteomics and phylogeny of mitochondrial glutathione S-transferase-kappa from the camel Camelus dromedaries. Research in Veterinary Science 97 (2014) 46–54
71. Ibrahim MM, Hazani AA, Al-Homidan A, Shehata A, El-Gaaly GA, Al-Jafari A, et al. Synthesis of Eco- Friendly silver nanoparticles using plant extracts and assessment of their antimicrobial activity  FRESENIUS ENVIRONMENTAL BULLETIN 2014, 23 (1A): 184-189
 
72. Al-Hazzani AA, Daoud MS, Ataya F, Fouad D, and Al-Jafari AA. Renin-angiotensin system gene polymorphisms among Saudi patients with coronary artery disease. Journal of Biological Research-Thessaloniki 2014, 21:8
73. Al-Jafari AA, Daoud MS, Ataya F, ACE Gene Insertion/Deletion Polymorphism in Coronary Artery Disease in the Saudi Population. Annals of Biological Research 2016, 8 (3):4-10
 
74. Mohammad Alanazi, Abdullah Al-Amri, Abdulaziz Al-Jafari, Abdulelah F Moberak, Sanaa A Ajaj, Jilani Shaik, Sooad Al-Daihan, Arjumand S Warsy, Narasimha Reddy Parine. Association of promoter region polymorphism in CYP19 gene to cardiovascular disease risk in Saudi cohort. Int J Clin Exp Pathol 2016; 9 (4)
 
75- Seema Zarger, Abdulaziz Al –Jafari and Tanveer A. Wani. Variants in MEF2A gene in relation with coronary artery disease in Saudi population. Biotech 2018; 8: 289-296
 
76.